Home > Insider Trading > Filing (0001246360-15-001488)

Filing Details

Accession Number:: 0001246360-15-001488
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-03-13 17:49:08
Reporting Period:: 2015-03-11

Filing Date:: 2015-03-13
Accepted Time:: 2015-03-13 17:49:08
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532217	Chris Heberlig	33 Hayden Ave Lexington MA 02421	Svp, Finance And Business Ops.	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-03-11	86	$76.88	390	No	4	A	Direct
Common Stock	Acquisiton	2015-03-11	7,500	$40.74	7,890	No	4	M	Direct
Common Stock	Disposition	2015-03-11	900	$100.44	6,990	No	4	S	Direct
Common Stock	Disposition	2015-03-11	600	$101.38	6,390	No	4	S	Direct
Common Stock	Disposition	2015-03-11	900	$102.46	5,490	No	4	S	Direct
Common Stock	Disposition	2015-03-11	3,290	$103.55	2,200	No	4	S	Direct
Common Stock	Disposition	2015-03-11	1,510	$104.57	690	No	4	S	Direct
Common Stock	Disposition	2015-03-11	300	$105.74	390	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2015-03-11	7,500	$0.00	7,500	$40.74

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,500		2022-06-27	No	4	M	Direct

Footnotes

The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Synageva BioPharma Corp. Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2014 through December 31, 2014. This transaction is also exempt under Rule 16b-3(c).
The reporting person is voluntarily reporting this transaction as of 03/11/2015, but the actual transaction took place on 12/31/2014, the last trading day of the option period under the ESPP.
In accordance with the ESPP, these shares were purchased based on 85% of the closing stock price on July 1, 2014, the first trading day of the option period.
The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 3, 2014.
The Stock Option granted the reporting person an option to purchase 15,000 Shares. 25% of such Shares vested and became exercisable on 06/27/2013, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $100.10 to $100.95. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.12 to $101.88. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.98 to $102.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $103.00 to $103.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $104.15 to $105.00. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $105.59 to $106.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.